Contineum Therapeutics In... (CTNM)
| Bid | 4.04 |
| Market Cap | 107.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.26M |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | -1.9 |
| Forward PE | -6.46 |
| Analyst | Buy |
| Ask | 4.6 |
| Volume | 63,423 |
| Avg. Volume (20D) | 59,818 |
| Open | 4.52 |
| Previous Close | 4.62 |
| Day's Range | 4.04 - 4.57 |
| 52-Week Range | 4.04 - 22.00 |
| Beta | 0.22 |
About CTNM
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). Th...
Analyst Forecast
According to 5 analyst ratings, the average rating for CTNM stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 503.86% from the latest price.
Stock Forecasts
4 weeks ago · businesswire.com
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS ForumSAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...
